Clinical Trial Update: Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51 [Phase 3]

View source ↗

Summary

Phase 3 trial of the IC51 Japanese encephalitis vaccine by Valneva Austria GmbH has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• IC51

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Japanese Encephalitis | Phase 3 | Status: COMPLETED | Results posted: 2014-03-26